Physician profile
Erich Hinel
NPI 1447563077
$8,619.61
in general payments reported to CMS, 2019-2025
25 companies · $1,542 in 2025
The $1,542 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,810 · 2020: $296 · 2021: $108 · 2022: $1,607 · 2023: $814 · 2024: $2,442 · 2025: $1,542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,898 · Consulting Fee: $900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,898.08 |
| Consulting Fee | $900.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $1,610.77 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $1,445.34 | 2024-2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $1,205.31 | 2019 | |
| Aerie Pharmaceuticals, INC. | $483.91 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $458.89 | 2022-2025 | Vyzulta, Xiidra, Miebo |
| Sun Pharmaceutical Industries INC. | $400.50 | 2019-2025 | Cequa |
| Dompe US, INC. | $357.00 | 2024-2025 | Oxervate |
| Harrow Eye, LLC | $336.03 | 2024-2025 | Vevye |
| Astellas Pharma US INC | $305.80 | 2023-2024 | Izervay |
| Alcon Vision LLC | $292.05 | 2022-2025 | Tryptyr, Simbrinza, Rocklatan |
| Abbvie INC. | $288.36 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $285.44 | 2022-2025 | Acthar |
| Oyster Point Pharma, INC. | $241.09 | 2022-2024 | Tyrvaya |
| Regeneron Healthcare Solutions, INC. | $210.94 | 2023-2025 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $152.46 | 2023-2025 | Syfovre |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $145.63 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $94.26 | 2024-2025 | Purified Cortrophin Gel, Yutiq |
| Novartis Pharmaceuticals Corporation | $85.16 | 2020-2023 | |
| Alimera Sciences, INC. | $80.76 | 2022-2024 | Yutiq, Iluvien |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $34.40 | 2020-2021 | |
| Kala Pharmaceuticals, INC. | $32.60 | 2019-2021 | |
| Lombart Brothers, INC. | $30.26 | 2019 | |
| Eyepoint US, INC. | $16.42 | 2019 | |
| Immunogen, INC. | $14.30 | 2023 | Elahere |
| Shire North American Group INC | $11.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erich Hinel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.